Human gastric carcinoma cell line (SNU-5)

Description

The SNU-5 cell line was established in 1987 by J. Park and colleagues from the ascites of a patient with poorly differentiated gastric cancer. The patient had previously received chemotherapy including 5-fluorouracil, doxorubicin, and mitomycin.

• The cells express the surface glycoprotein carcinoembryonic antigen (CEA) and TAG-72.
• The cells are positive for L-dopa decarboxylase (DDC).
• SNU-5 cells are positive for VIP receptors but lack gastrin receptors.
• They express muscarinic cholinergic factor receptors.
• There is no evidence of amplification or rearrangement of the N-myc, L-myc, myb, and EGF receptor genes.
• The cells express levels of c-myc and c-erb-B-2 RNA comparable to other cell lines.
• The following genes are not expressed: N-myc, L-myc, c-cis, IGF-2, or gastrin-releasing peptide.